Next Article in Journal
Bidirectional Relationships and Disconnects between NAFLD and Features of the Metabolic Syndrome
Next Article in Special Issue
Discovery of Dual ETA/ETB Receptor Antagonists from Traditional Chinese Herbs through in Silico and in Vitro Screening
Previous Article in Journal
A New Secondary Structure Assignment Algorithm Using Cα Backbone Fragments
Previous Article in Special Issue
Withaferin-A—A Natural Anticancer Agent with Pleitropic Mechanisms of Action
Article Menu
Issue 3 (March) cover image

Export Article

Open AccessReview
Int. J. Mol. Sci. 2016, 17(3), 358;

Molecular Selection, Modification and Development of Therapeutic Oligonucleotide Aptamers

Institute for Advancing Translational Medicine in Bone & Joint Diseases, School of Chinese Medicine, Hong Kong Baptist University, Hong Kong, China
Zhengzhou Hospital of Traditional Chinese Medicine, Zhengzhou 450007, China
Authors to whom correspondence should be addressed.
Academic Editor: Ritva Tikkanen
Received: 22 December 2015 / Revised: 1 February 2016 / Accepted: 29 February 2016 / Published: 11 March 2016
Full-Text   |   PDF [1482 KB, uploaded 11 March 2016]   |  


Monoclonal antibodies are the dominant agents used in inhibition of biological target molecules for disease therapeutics, but there are concerns of immunogenicity, production, cost and stability. Oligonucleotide aptamers have comparable affinity and specificity to targets with monoclonal antibodies whilst they have minimal immunogenicity, high production, low cost and high stability, thus are promising inhibitors to rival antibodies for disease therapy. In this review, we will compare the detailed advantages and disadvantages of antibodies and aptamers in therapeutic applications and summarize recent progress in aptamer selection and modification approaches. We will present therapeutic oligonucleotide aptamers in preclinical studies for skeletal diseases and further discuss oligonucleotide aptamers in different stages of clinical evaluation for various disease therapies including macular degeneration, cancer, inflammation and coagulation to highlight the bright commercial future and potential challenges of therapeutic oligonucleotide aptamers. View Full-Text
Keywords: oligonucleotide aptamers; monoclonal antibodies; diseases therapy; preclinical study; clinical evaluation oligonucleotide aptamers; monoclonal antibodies; diseases therapy; preclinical study; clinical evaluation

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Yu, Y.; Liang, C.; Lv, Q.; Li, D.; Xu, X.; Liu, B.; Lu, A.; Zhang, G. Molecular Selection, Modification and Development of Therapeutic Oligonucleotide Aptamers. Int. J. Mol. Sci. 2016, 17, 358.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top